Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivokin: F16IL2 + Nivolumab in NSCLC
NCT05468294Phase 2Unknown
- Sponsor
- Philogen
- Start
- Mar 2017
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teleleukin in non-small cell lung cancer (NSCLC), sponsored by Philogen. Primary endpoints: Dose Limiting Toxicities and Objective Response Rate at Week 24. Status: unknown.
02
Drugs
teleleukin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05468294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05468294.